Baxter International Inc.


SKU: BAX Category:


This is our first report on Baxter International, one of the largest players in the domain of dialysis therapies and other healthcare products. The company’s results for the last quarter were strong and it surpassed revenue expectations of Wall Street despite the fact that sales were impacted by specific supply chain-related issues. Sales for the entire company increased by 23% at constant exchange rates and 17% on a reported basis, totalling $3.8 billion of which Hillrom’s sales were $735 million. Their legacy organization’s integration is moving along quickly, and they are capturing more value through cost savings than they had anticipated. The overall demand for products across the Baxter and traditional Hillrom portfolios continues to be strong. But they continue to have significant backlogs of orders because of the restricted access to several raw materials and electromechanical parts. Besides, their overall demand planning procedure was significantly impacted by several decommitments from different suppliers. Performance has further been affected by supply restrictions caused by other raw material shortages. The company also met market expectations with respect to earnings as the management continued to focus on improving patient outcomes, boosting workflow effectiveness, and enabling cost-effective care. We initiate coverage on the stock of Baxter International with a ‘Buy’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!